Details for Patent: 10,583,121
✉ Email this page to a colleague
Which drugs does patent 10,583,121 protect, and when does it expire?
Patent 10,583,121 protects SECUADO and is included in one NDA.
This patent has thirty-eight patent family members in nine countries.
Summary for Patent: 10,583,121
| Title: | Patch |
| Abstract: | A patch for administering asenapine includes a support layer, and an adhesive agent layer formed on the support layer and including an adhesive base agent and asenapine and/or a pharmaceutically acceptable salt thereof. The adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and includes a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, a styrene-isoprene-styrene block copolymer, or a combination thereof. When a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC.sub.2-120 for a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pghr/mL or more, and an AUC.sub.2-120 of an asenapine metabolite is 20% or less of the AUC.sub.2-120 of the free asenapine. |
| Inventor(s): | Suzuki; Masayuki (Tsukuba, JP), Okutsu; Hiroaki (Tsukuba, JP), Yasukochi; Takashi (Tsukuba, JP), Takada; Yasunori (Tsukuba, JP) |
| Assignee: | HISAMITSU PHARMACEUTICAL CO., INC. (Tosu-shi, JP) |
| Application Number: | 15/454,066 |
|
Patent Claim Types: see list of patent claims | Use; Compound; |
Drugs Protected by US Patent 10,583,121
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-001 | Oct 11, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH | ⤷ Try a Trial | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-002 | Oct 11, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH | ⤷ Try a Trial | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-003 | Oct 11, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,583,121
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2012-165793 | Jul 26, 2012 |
| Japan | 2013-078583 | Apr 4, 2013 |
International Family Members for US Patent 10,583,121
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| China | 104487071 | ⤷ Try a Trial | |||
| China | 104487072 | ⤷ Try a Trial | |||
| China | 104507472 | ⤷ Try a Trial | |||
| European Patent Office | 2878298 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
